Ralinepag — Milestone payment to be made
United Therapeutics Ralinepag — Milestone payment to be made remained flat by 0.0% to $62.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $62.50M to $62.50M. Over 4 years (FY 2021 to FY 2025), Ralinepag — Milestone payment to be made shows relatively stable performance with a 0.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase indicates higher future cash outflows tied to development progress, while a decrease suggests either the completion of obligations or a reduction in the scope of the development program.
Detailed definition
This metric represents the future financial obligations associated with achieving specific development, regulatory, or c...
Peer comparison
Commonly seen in biotech and pharmaceutical companies as 'contingent consideration' or 'milestone obligations' in licensing agreements or acquisition contracts.
uthr_segment_ralinepag_milestone_payment_to_be_madeHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $250.00M | $250.00M | $250.00M | $250.00M | $250.00M |
| YoY Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's ralinepag — milestone payment to be made?
- United Therapeutics (UTHR) reported ralinepag — milestone payment to be made of $62.50M in Q4 2025.
- How has United Therapeutics's ralinepag — milestone payment to be made changed year-over-year?
- United Therapeutics's ralinepag — milestone payment to be made decreased by 0.0% year-over-year, from $62.50M to $62.50M.
- What is the long-term trend for United Therapeutics's ralinepag — milestone payment to be made?
- Over 4 years (2021 to 2025), United Therapeutics's ralinepag — milestone payment to be made has grown at a 0.0% compound annual growth rate (CAGR), from $250.00M to $250.00M.
- What does ralinepag — milestone payment to be made mean?
- The total amount of future payments owed to third parties upon reaching specific development or regulatory goals for a drug candidate.